Can Targeted Drugs and Immunotherapy Treat Ampullary Cancer?

Yes, there are targeted therapies and immunotherapies available, but they are not used for every patient. Treatment for ampullary cancer (carcinoma of the ampulla of Vater) depends heavily on the stage of the disease, whether the tumor can be removed by surgery, and whether its cells look more like intestinal or pancreatic tissue ^[1][2].

Targeted therapies and immunotherapies are generally considered for advanced, recurrent, or metastatic disease when standard treatments like surgery or initial chemotherapy are no longer sufficient ^[1]. When these drugs are used, they are chosen based on specific genetic vulnerabilities found inside the cancer cells.

The Role of Biomarker Testing and Molecular Profiling

To find these vulnerabilities, doctors use biomarker testing. This includes immunohistochemistry (IHC), which looks for specific proteins on the surface of the cells, and Next-Generation Sequencing (NGS), a laboratory test that analyzes the tumor’s DNA and RNA for mutations ^[3][4].

Because ampullary cancer is rare and biologically diverse, comprehensive testing is highly recommended, especially in advanced disease ^[5]. However, finding a genetic mutation (often called an “actionable mutation”) does not guarantee a cure. It simply identifies potential options, which might include an approved drug, an off-label treatment (using a drug approved for a different cancer), or a clinical trial ^[6].

Immunotherapy and MSI-H/dMMR

Immunotherapies are drugs that help your own immune system recognize and attack cancer cells. For ampullary cancer, the most important markers for immunotherapy are Mismatch Repair Deficiency (dMMR) and Microsatellite Instability-High (MSI-H).

MMR genes normally act like spell-checkers for your DNA. When they fail (dMMR), genetic errors pile up, leading to high instability (MSI-H) ^[7]. Up to 18% of ampullary cancers, particularly those of the intestinal subtype, have this feature ^[7][8].

If testing (usually via IHC) shows your tumor is MSI-H or dMMR, you may be eligible for an immunotherapy drug called pembrolizumab. In the U.S., the FDA has granted a “tissue-agnostic” approval for pembrolizumab to treat any unresectable or metastatic MSI-H/dMMR solid tumor that has progressed after prior treatment and for which there are no satisfactory alternative options ^[7][8].

Safety and genetics note: Immunotherapies can cause your immune system to become overactive, leading to potentially serious inflammation in healthy organs like the bowel, lungs, or liver. Additionally, finding out if dMMR is present is important for your family, as it may indicate an inherited risk called Lynch syndrome. This finding should prompt a discussion about genetic counseling ^[4].

Targeted Therapies for Specific Mutations

Targeted drugs are designed to interfere with specific molecules driving cancer growth. Your eligibility for these drugs depends entirely on whether your tumor has the corresponding mutation.

HER2 (ERBB2) Alterations

HER2 is a protein that can cause cancer cells to grow quickly. Approximately 11% to 13% of ampullary cancers show high levels of this protein or extra copies of its gene ^[9][10]. If IHC testing confirms high HER2 levels (specifically a score of IHC 3+), you may be a candidate for HER2-targeted drugs ^[11]. For example, trastuzumab deruxtecan has a tissue-agnostic FDA approval for previously treated, unresectable, or metastatic HER2-positive solid tumors when no satisfactory alternatives exist ^[12].
Safety note: Trastuzumab deruxtecan carries a serious risk of severe lung inflammation (interstitial lung disease or pneumonitis). Any new cough or shortness of breath must be reported to your oncology team immediately ^[12].

BRCA1, BRCA2, and DNA Repair Genes

A small but important proportion of ampullary cancers carry mutations in DNA repair genes, such as BRCA1, BRCA2, or ATM ^[13][14]. These can be inherited (germline) or occur only within the tumor (somatic). While there is no ampullary-specific drug approval for these mutations, finding them might prompt your doctor to consider a class of drugs called PARP inhibitors or platinum-based chemotherapy. These are often accessed through a clinical trial or careful off-label use ^[13]. Tumor testing cannot replace inherited genetic testing; finding a tumor mutation often requires a separate blood or saliva test to see if it runs in your family ^[14].

KRAS Mutations

KRAS mutations are very common, found in about 30% to 45% of ampullary cancers ^[15]. It is important to know that most of these mutations (like G12D or G12V) do not yet have approved targeted drugs. A very small fraction involves a specific mutation called KRAS G12C, which has targeted drugs approved in other cancers (like lung cancer) ^[16]. Identifying your exact KRAS status helps guide expectations and trial eligibility, rather than providing an automatic immediate treatment ^[15][16].

The Importance of Clinical Trials

Because this cancer is rare, patients may access emerging targeted therapies through basket trials ^[6]. These trials enroll patients based on their specific genetic mutation (like HER2 or a specific KRAS variant) regardless of where the cancer started. However, a mutation alone does not guarantee a spot in a trial; you must also meet strict criteria regarding your overall health, organ function, and previous treatments ^[6]. Always discuss comprehensive biomarker testing with your oncologist to see if these modern treatments are an appropriate option for your specific situation.